Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: A Literature Review and Our Own Experience
Authors:
- Ulyana Gordeevna KoshkinaUKUlyana Gordeevna Koshkina
- A. A. SemenovaASA. A. Semenova
- M. Yu. KichiginaMKM. Yu. Kichigina
- D. N. TupitsynaDTD. N. Tupitsyna
- V. O. ShpirkoVSV. O. Shpirko
- A. I. CherencovaACA. I. Cherencova
- S. F. RamazanovaSRS. F. Ramazanova
- N. O. ZemlyakovNZN. O. Zemlyakov
- I. Z. ZavodnovaIZI. Z. Zavodnova
- A. V. ArakelyanAAA. V. Arakelyan
- G. D. PetrovaGPG. D. Petrova
- O. Yu. BaranovaOBO. Yu. Baranova
Open Access
- 1 January 2026
- journal article
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1)
Abstract
AIM. To assess the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKi) as first and subsequent lines of mantle cell lymphoma (MCL) therapy. MATERIALS & METHODS. This study enrolled 30 patients with newly diagnosed (ndMCL; n = 17) and relapsed/refractory MCL (r/r MCL; n = 13) treated with BTKi at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center during 2016–2025. NdMCL patients less than 60 years of age (n = 10/17; 58 %) were treated with alternating regimen R-CHOP + I/R-DHAOx combined with BTKi, 6 of them received high-dose chemotherapy with autologous hematopoietic stem cell transplantation. Elderly ndMCL patients (n = 7/17; 41 %) were treated with R-B program combined with BTKi. Irrespective of the induction phase, rituximab maintenance therapy (3 years) and BTKi (2 years) were administered to all patients. For the treatment of r/r MCL, BTKi was used as a monoregimen in 6 (46 %) patients, 2 (15 %) patients received it in combination with R-B, and 5 (38 %) in combination with rituximab. RESULTS. With the median follow-up of 36 months, ndMCL patients (n = 17) showed the 3-year progression-free survival (PFS) of 81.4 % and the 3-year overall survival (OS) of 84.4 %. In the r/r MCL group, with the median follow-up of 22 months, the 3-year PFS was 60.9 %, and the 3-year OS was 67 %. During this time, in the period from 3 to 23 months, 3 patients died (2 of them due to disease progression and 1 died from an infection). Toxicity profile of BTKi combination appeared to be manageable, whereas more infectious complications (53.8 % vs. 35.3 %) and more cases of pneumonia (53.8 vs. 29.4 %) were observed in r/r MCL vs. ndMCL patients. CONCLUSION. The administration of BTKi combined with chemotherapy is associated with high efficacy and favorable toxicity profile in the treatment of both ndMCL and r/r MCL.Keywords
This publication has 21 references indexed in Scilit:
- Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkThe Lancet, 2024
- Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaNew England Journal of Medicine, 2022
- Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialThe Lancet Oncology, 2022
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaNew England Journal of Medicine, 2018
- TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapyBlood, 2017
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting pathological B cell receptor signalling in lymphoid malignanciesNature Reviews Drug Discovery, 2013
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical FeaturesCancer Research, 2012
- Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell LymphomaCancer Research, 2010
- From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decadesHuman Pathology, 2002